Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The mechanistic target of rapamycin (mTOR) pathway is crucial for cell growth and survival, with its dysregulation implicated in cancer development and treatment resistance.
• Current mTORC1 inhibitors like Rapamycin have limited efficacy, necessitating novel therapeutic strategies.
• mTOR exists in two complexes, mTORC1 and mTORC2, both involved in cellular processes relevant to cancer.

Purpose of the Study:

• To review the role of the mTOR pathway and the Fanconi anemia pathway in cancer.
• To highlight the newly discovered connection between mTOR inhibition and the Fanconi anemia pathway.
• To explore the potential of dual mTORC1/mTORC2 inhibitors in overcoming cancer drug resistance.

Main Methods:

• Literature review focusing on mTOR signaling, Fanconi anemia pathway, and cancer therapeutics.
• Analysis of preclinical and clinical studies on mTOR inhibitors.
• Investigation of the molecular mechanisms linking mTOR inhibition to DNA repair pathways.

Main Results:

• Dual mTORC1/mTORC2 inhibitors demonstrate greater efficacy than first-generation inhibitors in preclinical and clinical settings.
• Dual mTORC1/mTORC2 inhibitors sensitize leukemia and rhabdomyosarcoma cells to DNA-damaging agents.
• This sensitization is mediated by the suppression of FANCD2 expression within the Fanconi anemia DNA repair pathway.

Conclusions:

• Dual mTORC1/mTORC2 inhibitors represent a promising therapeutic approach for various cancers.
• Targeting the interplay between mTOR signaling and the Fanconi anemia pathway offers a novel strategy to enhance chemotherapy effectiveness.
• Further research into this connection may lead to improved treatment outcomes for patients with drug-resistant cancers.